Company Number: 12616379

Analysis Date: 2025-07-29 14:18 UTC

1. Credit Opinion: APPROVE

Northwest Laboratories Limited demonstrates improving financial health with a significant increase in net assets and working capital over the past two years. The company shows sound financial stewardship and no negative director conduct records, supporting confidence in management. The micro-entity reporting exemption and absence of an audit do require cautious interpretation, but the positive trends and current financial position justify approval for credit facilities under prudent risk limits.

2. Financial Strength:

• Net assets have risen substantially from £6,907 in 2020 to £170,971 in 2024, reflecting strong equity growth.
• Fixed assets are stable around £130,000, indicating investment in long-term operational capacity.
• The company has moved from a net current liability position in 2020 (£-45,397) to a net current asset position in 2024 (£39,844), improving short-term solvency.
• Shareholders' funds have increased from £6,907 to £170,971, illustrating retained earnings or capital injection, strengthening the balance sheet.

3. Cash Flow Assessment:

• Current assets rose from £32,028 in 2023 to £95,750 in 2024, mostly improving liquidity.
• Current liabilities reduced significantly from £134,172 to £67,131, indicating better management of short-term obligations.
• Net current assets are positive at £39,844, suggesting sufficient working capital to cover immediate liabilities.
• The average number of employees is small (4 in 2024), implying relatively low fixed overheads.
• No cash flow statement is provided, but the increase in working capital and reduced creditors point to improved cash management.

4. Monitoring Points:

• Continue monitoring the liquidity position and working capital, ensuring current assets remain sufficient to cover liabilities.
• Observe any changes in trade creditors and debtor collections that could impact cash flow.
• Review future accounts for continued growth in net assets and profitability given the absence of profit & loss details.
• Monitor director appointment changes and any potential related party transactions given two directors share the surname Gallagher.
• Keep an eye on industry risks within technical testing and analysis, especially any regulatory or market shifts affecting revenues.